Clinical Trial Detail

NCT ID NCT03913559
Title Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors St. Jude Children's Research Hospital
Indications

B-cell adult acute lymphocytic leukemia

childhood B-cell acute lymphoblastic leukemia

Therapies

inotuzumab ozogamicin

Cytarabine + Hydrocortisone + Methotrexate

Acetaminophen + Diphenhydramine + Methylprednisolone

Age Groups: child adult

No variant requirements are available.